Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells

Takahiro Yoshioka, Kazuhiko Shien, Tatsuaki Takeda, Yuta Takahashi, Eisuke Kurihara, Yusuke Ogoshi, Kei Namba, Hidejiro Torigoe, Hiroki Sato, Shuta Tomida, Hiromasa Yamamoto, Junichi Sou, Toshiyoshi Fujiwara, Shinichi Toyooka

Research output: Contribution to journalArticle

Abstract

Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to evolve, with the development of genome analysis technology and the advent of molecular targeted drugs including tyrosine kinase inhibitors. Nevertheless, acquired drug resistance to molecular targeted drugs is unavoidable, creating a clinically challenging problem. We recently reported the antitumor effect of a pan-HER inhibitor, afatinib, against human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer cells. The purpose of the present study was to identify the mechanisms of acquired afatinib resistance and to investigate the treatment strategies for HER2-amplified gastric cancer cells. Two afatinib-resistant gastric cancer cell lines were established from 2 HER2-amplified cell lines, N87 and SNU216. Subsequently, we investigated the molecular profiles of resistant cells. The activation of the HER2 pathway was downregulated in N87-derived resistant cells, whereas it was upregulated in SNU216-derived resistant cells. In the N87-derived cell line, both MET and AXL were activated, and combination treatment with afatinib and cabozantinib, a multikinase inhibitor that inhibits MET and AXL, suppressed the cell growth of cells with acquired resistance both in vitro and in vivo. In the SNU216-derived cell line, YES1, which is a member of the Src family, was remarkably activated, and dasatinib, a Src inhibitor, exerted a strong antitumor effect in these cells. In conclusion, we identified MET and AXL activation in addition to YES1 activation as novel mechanisms of afatinib resistance in HER2-driven gastric cancer. Our results also indicated that treatment strategies targeting individual mechanisms of resistance are key to overcoming such resistance.

Original languageEnglish
JournalCancer Science
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Stomach Neoplasms
Cell Line
BIBW 2992
human ERBB2 protein
Drug Resistance
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Lung Neoplasms
Down-Regulation
Genome
Breast Neoplasms
Technology
Growth
Neoplasms

Keywords

  • afatinib
  • gastric cancer
  • HER2
  • MET
  • YES1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells. / Yoshioka, Takahiro; Shien, Kazuhiko; Takeda, Tatsuaki; Takahashi, Yuta; Kurihara, Eisuke; Ogoshi, Yusuke; Namba, Kei; Torigoe, Hidejiro; Sato, Hiroki; Tomida, Shuta; Yamamoto, Hiromasa; Sou, Junichi; Fujiwara, Toshiyoshi; Toyooka, Shinichi.

In: Cancer Science, 01.01.2019.

Research output: Contribution to journalArticle

Yoshioka, Takahiro ; Shien, Kazuhiko ; Takeda, Tatsuaki ; Takahashi, Yuta ; Kurihara, Eisuke ; Ogoshi, Yusuke ; Namba, Kei ; Torigoe, Hidejiro ; Sato, Hiroki ; Tomida, Shuta ; Yamamoto, Hiromasa ; Sou, Junichi ; Fujiwara, Toshiyoshi ; Toyooka, Shinichi. / Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells. In: Cancer Science. 2019.
@article{a03fb370a3cf4b0392c4f2c277f7f769,
title = "Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells",
abstract = "Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to evolve, with the development of genome analysis technology and the advent of molecular targeted drugs including tyrosine kinase inhibitors. Nevertheless, acquired drug resistance to molecular targeted drugs is unavoidable, creating a clinically challenging problem. We recently reported the antitumor effect of a pan-HER inhibitor, afatinib, against human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer cells. The purpose of the present study was to identify the mechanisms of acquired afatinib resistance and to investigate the treatment strategies for HER2-amplified gastric cancer cells. Two afatinib-resistant gastric cancer cell lines were established from 2 HER2-amplified cell lines, N87 and SNU216. Subsequently, we investigated the molecular profiles of resistant cells. The activation of the HER2 pathway was downregulated in N87-derived resistant cells, whereas it was upregulated in SNU216-derived resistant cells. In the N87-derived cell line, both MET and AXL were activated, and combination treatment with afatinib and cabozantinib, a multikinase inhibitor that inhibits MET and AXL, suppressed the cell growth of cells with acquired resistance both in vitro and in vivo. In the SNU216-derived cell line, YES1, which is a member of the Src family, was remarkably activated, and dasatinib, a Src inhibitor, exerted a strong antitumor effect in these cells. In conclusion, we identified MET and AXL activation in addition to YES1 activation as novel mechanisms of afatinib resistance in HER2-driven gastric cancer. Our results also indicated that treatment strategies targeting individual mechanisms of resistance are key to overcoming such resistance.",
keywords = "afatinib, gastric cancer, HER2, MET, YES1",
author = "Takahiro Yoshioka and Kazuhiko Shien and Tatsuaki Takeda and Yuta Takahashi and Eisuke Kurihara and Yusuke Ogoshi and Kei Namba and Hidejiro Torigoe and Hiroki Sato and Shuta Tomida and Hiromasa Yamamoto and Junichi Sou and Toshiyoshi Fujiwara and Shinichi Toyooka",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/cas.14089",
language = "English",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells

AU - Yoshioka, Takahiro

AU - Shien, Kazuhiko

AU - Takeda, Tatsuaki

AU - Takahashi, Yuta

AU - Kurihara, Eisuke

AU - Ogoshi, Yusuke

AU - Namba, Kei

AU - Torigoe, Hidejiro

AU - Sato, Hiroki

AU - Tomida, Shuta

AU - Yamamoto, Hiromasa

AU - Sou, Junichi

AU - Fujiwara, Toshiyoshi

AU - Toyooka, Shinichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to evolve, with the development of genome analysis technology and the advent of molecular targeted drugs including tyrosine kinase inhibitors. Nevertheless, acquired drug resistance to molecular targeted drugs is unavoidable, creating a clinically challenging problem. We recently reported the antitumor effect of a pan-HER inhibitor, afatinib, against human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer cells. The purpose of the present study was to identify the mechanisms of acquired afatinib resistance and to investigate the treatment strategies for HER2-amplified gastric cancer cells. Two afatinib-resistant gastric cancer cell lines were established from 2 HER2-amplified cell lines, N87 and SNU216. Subsequently, we investigated the molecular profiles of resistant cells. The activation of the HER2 pathway was downregulated in N87-derived resistant cells, whereas it was upregulated in SNU216-derived resistant cells. In the N87-derived cell line, both MET and AXL were activated, and combination treatment with afatinib and cabozantinib, a multikinase inhibitor that inhibits MET and AXL, suppressed the cell growth of cells with acquired resistance both in vitro and in vivo. In the SNU216-derived cell line, YES1, which is a member of the Src family, was remarkably activated, and dasatinib, a Src inhibitor, exerted a strong antitumor effect in these cells. In conclusion, we identified MET and AXL activation in addition to YES1 activation as novel mechanisms of afatinib resistance in HER2-driven gastric cancer. Our results also indicated that treatment strategies targeting individual mechanisms of resistance are key to overcoming such resistance.

AB - Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to evolve, with the development of genome analysis technology and the advent of molecular targeted drugs including tyrosine kinase inhibitors. Nevertheless, acquired drug resistance to molecular targeted drugs is unavoidable, creating a clinically challenging problem. We recently reported the antitumor effect of a pan-HER inhibitor, afatinib, against human epidermal growth factor receptor 2 (HER2)-amplified gastric cancer cells. The purpose of the present study was to identify the mechanisms of acquired afatinib resistance and to investigate the treatment strategies for HER2-amplified gastric cancer cells. Two afatinib-resistant gastric cancer cell lines were established from 2 HER2-amplified cell lines, N87 and SNU216. Subsequently, we investigated the molecular profiles of resistant cells. The activation of the HER2 pathway was downregulated in N87-derived resistant cells, whereas it was upregulated in SNU216-derived resistant cells. In the N87-derived cell line, both MET and AXL were activated, and combination treatment with afatinib and cabozantinib, a multikinase inhibitor that inhibits MET and AXL, suppressed the cell growth of cells with acquired resistance both in vitro and in vivo. In the SNU216-derived cell line, YES1, which is a member of the Src family, was remarkably activated, and dasatinib, a Src inhibitor, exerted a strong antitumor effect in these cells. In conclusion, we identified MET and AXL activation in addition to YES1 activation as novel mechanisms of afatinib resistance in HER2-driven gastric cancer. Our results also indicated that treatment strategies targeting individual mechanisms of resistance are key to overcoming such resistance.

KW - afatinib

KW - gastric cancer

KW - HER2

KW - MET

KW - YES1

UR - http://www.scopus.com/inward/record.url?scp=85068072139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068072139&partnerID=8YFLogxK

U2 - 10.1111/cas.14089

DO - 10.1111/cas.14089

M3 - Article

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

ER -